| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
29,725,000 as of 6/30 |
| Market
Cap: |
409.91(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$6.11 - $14.51 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Drug Manufacturers - Major |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
Company Profile Endocyte is a biopharmaceutical company developing targeted therapies for the treatment of cancer and inflammatory diseases. Co. uses its technology to create small molecule drug conjugates (SMDCs), and companion imaging diagnostics. Co.'s main SMDC, EC145, targets the folate receptor, which is over-expressed on cancer cells, primarily platinum-resistant ovarian cancer, a treatment-resistant disease. Co. is also developing its main companion imaging diagnostic, EC20, and the analysis of tumor biopsies has shown that the folate receptor is also over-expressed in a range of other solid tumors including non-small cell lung, breast, colorectal, kidney, endometrial and other cancers.
|
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
669,178 |
| Total Buy Value |
$0 |
$0 |
$0 |
$2,149,908 |
| Total People Bought |
0 |
0 |
0 |
7 |
| Total Buy Transactions |
0 |
0 |
0 |
13 |
| Total Shares Sold |
147,285 |
165,912 |
544,430 |
719,330 |
| Total Sell Value |
$2,113,646 |
$2,283,832 |
$4,958,064 |
$6,152,852 |
| Total People Sold |
6 |
6 |
7 |
7 |
| Total Sell Transactions |
18 |
27 |
34 |
37 |
| End Date |
2013-02-22 |
2012-11-21 |
2012-05-23 |
2011-05-24 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Nguyen Binh |
VP of Clinical Affairs |
• – – |
2013-05-22 |
4 |
OE |
$3.55 |
$9,585 |
D/D |
2,700 |
2,700 |
|
- |
|
| Hanham Ann |
Director |
– • – |
2013-05-22 |
4 |
S |
$14.39 |
$235,996 |
I/I |
(16,400) |
54,926 |
|
- |
|
| Hanham Ann |
Director |
– • – |
2013-05-21 |
4 |
S |
$14.31 |
$157,410 |
I/I |
(11,000) |
56,185 |
|
- |
|
| Ritter Allen R |
VP of Manufacturing/CMC |
• – – |
2013-05-21 |
4 |
AS |
$14.17 |
$6,844 |
D/D |
(483) |
12,722 |
|
- |
|
| Hanham Ann |
Director |
– • – |
2013-05-20 |
4 |
S |
$14.42 |
$181,692 |
I/I |
(12,600) |
57,030 |
|
- |
|
| Hanham Ann |
Director |
– • – |
2013-05-17 |
4 |
S |
$14.37 |
$209,802 |
I/I |
(14,600) |
57,997 |
|
- |
|
| Nguyen Binh |
VP of Clinical Affairs |
• – – |
2013-05-17 |
4 |
OE |
$3.55 |
$61,415 |
D/D |
17,300 |
17,300 |
|
- |
|
| Nguyen Binh |
VP of Clinical Affairs |
• – – |
2013-05-17 |
4 |
S |
$14.42 |
$249,466 |
D/D |
(17,300) |
0 |
|
- |
|
| Hanham Ann |
Director |
– • – |
2013-05-16 |
4 |
S |
$14.44 |
$326,344 |
I/I |
(22,600) |
59,118 |
|
1% |
|
| Hanham Ann |
Director |
– • – |
2013-05-15 |
4 |
S |
$14.43 |
$288,600 |
I/I |
(20,000) |
60,853 |
|
2% |
|
| Hanham Ann |
Director |
– • – |
2013-05-14 |
4 |
S |
$14.94 |
$301,788 |
I/I |
(20,200) |
62,389 |
|
2% |
|
| Leamon Christopher P |
Vice President of Research |
• – – |
2013-05-14 |
4 |
S |
$14.70 |
$73,500 |
D/D |
(5,000) |
10,073 |
|
2% |
|
| Ritter Allen R |
VP of Manufacturing/CMC |
• – – |
2013-05-07 |
4 |
AS |
$13.51 |
$6,755 |
D/D |
(500) |
13,205 |
|
6% |
|
| Ellis P Ron |
President and CEO |
• • – |
2013-05-01 |
4 |
AS |
$13.88 |
$6,940 |
D/D |
(500) |
29,154 |
|
5% |
|
| Ritter Allen R |
VP of Manufacturing/CMC |
• – – |
2013-04-16 |
4 |
AS |
$13.22 |
$6,610 |
D/D |
(500) |
13,705 |
|
3% |
|
| Ritter Allen R |
VP of Manufacturing/CMC |
• – – |
2013-04-02 |
4 |
AS |
$12.48 |
$6,240 |
D/D |
(500) |
14,205 |
|
8% |
|
| Ellis P Ron |
President and CEO |
• • – |
2013-04-01 |
4 |
AS |
$12.54 |
$6,270 |
D/D |
(500) |
29,654 |
|
15% |
|
| Ellis P Ron |
President and CEO |
• • – |
2013-03-27 |
4 |
AS |
$12.00 |
$18,000 |
D/D |
(1,500) |
30,154 |
|
19% |
|
| Ritter Allen R |
VP of Manufacturing/CMC |
• – – |
2013-03-25 |
4 |
AS |
$11.00 |
$11,000 |
D/D |
(1,000) |
14,705 |
|
35% |
|
| Ritter Allen R |
VP of Manufacturing/CMC |
• – – |
2013-03-13 |
4 |
OE |
$1.91 |
$24,299 |
D/D |
12,722 |
15,705 |
|
- |
|
| Lovejoy Chandra D |
VP of Regulatory Affairs |
• – – |
2013-02-25 |
4 |
AS |
$9.70 |
$20,389 |
D/D |
(2,102) |
0 |
|
56% |
|
| Lovejoy Chandra D |
VP of Regulatory Affairs |
• – – |
2013-02-25 |
4 |
OE |
$2.54 |
$6,356 |
D/D |
2,102 |
1,993 |
|
- |
|
| Ritter Allen R |
VP of Manufacturing/CMC |
• – – |
2013-02-19 |
4 |
AS |
$10.03 |
$5,015 |
D/D |
(500) |
2,983 |
|
45% |
|
| Ritter Allen R |
VP of Manufacturing/CMC |
• – – |
2013-02-15 |
4 |
AS |
$10.00 |
$5,000 |
D/D |
(500) |
3,483 |
|
43% |
|
| Ritter Allen R |
VP of Manufacturing/CMC |
• – – |
2013-01-31 |
4 |
AS |
$10.00 |
$10,000 |
D/D |
(1,000) |
3,983 |
|
42% |
|
96 Records found
|
|
Page 1 of 4 |
|
|
0.37 (2.61%) 
